Differential functions of RhoGDIβ in malignant transformation and progression of urothelial cell following N-butyl-N-(4-hydmoxybutyl) nitrosamine exposure.
Bladder carcinogenesis
Cancer invasion
RhoGDIβ
Tumor promotion/progression
Journal
BMC biology
ISSN: 1741-7007
Titre abrégé: BMC Biol
Pays: England
ID NLM: 101190720
Informations de publication
Date de publication:
28 08 2023
28 08 2023
Historique:
received:
09
10
2022
accepted:
15
08
2023
medline:
29
8
2023
pubmed:
28
8
2023
entrez:
27
8
2023
Statut:
epublish
Résumé
Functional role of Rho GDP-dissociation inhibitor beta (RhoGDIβ) in tumor biology appears to be contradictory across various studies. Thus, the exploration of the molecular mechanisms underlying the differential functions of this protein in urinary bladder carcinogenesis is highly significant in the field. Here, RhoGDIβ expression patterns, biological functions, and mechanisms leading to transformation and progression of human urothelial cells (UROtsa cells) were evaluated following varying lengths of exposure to the bladder carcinogen N-butyl-N-(4-hydmoxybutyl) nitrosamine (BBN). It was seen that compared to expression in vehicle-treated control cells, RhoGDIβ protein expression was downregulated after 2-month of BBN exposure, but upregulated after 6-month of exposure. Assessments of cell function showed that RhoGDIβ inhibited UROtsa cell growth in cells with BBN for 2-month exposure, whereas it promoted the invasion of cells treated with BBN for 6 months. Mechanistic studies revealed that 2-month of BBN exposure markedly attenuated DNMT3a abundance, and this led to reduced miR-219a promoter methylation, increased miR-219a binding to the RhoGDIβ mRNA 3'UTR, and reduced RhoGDIβ protein translation. While after 6-mo of BBN treatment, the cells showed increased PP2A/JNK/C-Jun axis phosphorylation and this in turn mediated overall RhoGDIβ mRNA transcription and protein expression as well as invasion. These findings indicate that RhoGDIβ is likely to inhibit the transformation of human urothelial cells during the early phase of BBN exposure, whereas it promotes invasion of the transformed/progressed urothelial cells in the late stage of BBN exposure. The studies also suggest that RhoGDIβ may be a useful biomarker for evaluating the progression of human bladder cancers.
Sections du résumé
BACKGROUND
Functional role of Rho GDP-dissociation inhibitor beta (RhoGDIβ) in tumor biology appears to be contradictory across various studies. Thus, the exploration of the molecular mechanisms underlying the differential functions of this protein in urinary bladder carcinogenesis is highly significant in the field. Here, RhoGDIβ expression patterns, biological functions, and mechanisms leading to transformation and progression of human urothelial cells (UROtsa cells) were evaluated following varying lengths of exposure to the bladder carcinogen N-butyl-N-(4-hydmoxybutyl) nitrosamine (BBN).
RESULTS
It was seen that compared to expression in vehicle-treated control cells, RhoGDIβ protein expression was downregulated after 2-month of BBN exposure, but upregulated after 6-month of exposure. Assessments of cell function showed that RhoGDIβ inhibited UROtsa cell growth in cells with BBN for 2-month exposure, whereas it promoted the invasion of cells treated with BBN for 6 months. Mechanistic studies revealed that 2-month of BBN exposure markedly attenuated DNMT3a abundance, and this led to reduced miR-219a promoter methylation, increased miR-219a binding to the RhoGDIβ mRNA 3'UTR, and reduced RhoGDIβ protein translation. While after 6-mo of BBN treatment, the cells showed increased PP2A/JNK/C-Jun axis phosphorylation and this in turn mediated overall RhoGDIβ mRNA transcription and protein expression as well as invasion.
CONCLUSIONS
These findings indicate that RhoGDIβ is likely to inhibit the transformation of human urothelial cells during the early phase of BBN exposure, whereas it promotes invasion of the transformed/progressed urothelial cells in the late stage of BBN exposure. The studies also suggest that RhoGDIβ may be a useful biomarker for evaluating the progression of human bladder cancers.
Identifiants
pubmed: 37635218
doi: 10.1186/s12915-023-01683-2
pii: 10.1186/s12915-023-01683-2
pmc: PMC10463823
doi:
Substances chimiques
rho Guanine Nucleotide Dissociation Inhibitor beta
0
Nitrosamines
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
181Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Mol Oncol. 2017 Nov;11(11):1579-1594
pubmed: 28846829
Clin Cancer Res. 2004 Jun 1;10(11):3800-6
pubmed: 15173088
Nature. 2002 Dec 12;420(6916):629-35
pubmed: 12478284
Clin Cancer Res. 2009 Apr 15;15(8):2612-9
pubmed: 19351766
Gene. 2017 Mar 10;604:1-8
pubmed: 27998789
Nat Cancer. 2021 Mar;2(3):271-283
pubmed: 33870211
Cancer Lett. 2018 Nov 1;436:38-51
pubmed: 30118841
Oncol Rep. 2007 Jun;17(6):1383-9
pubmed: 17487395
Oncogene. 2018 Apr;37(14):1911-1925
pubmed: 29367767
Br J Haematol. 2007 Oct;139(2):217-23
pubmed: 17897297
Cancer Lett. 2020 Nov 1;492:136-146
pubmed: 32860848
Cancer Res. 2005 May 1;65(9):3531-4
pubmed: 15867343
Curr Opin Cell Biol. 1996 Apr;8(2):205-15
pubmed: 8791420
Tanpakushitsu Kakusan Koso. 1996 Nov;41(15 Suppl):2288-95
pubmed: 8952391
Neuro Oncol. 2016 Jun;18(6):830-9
pubmed: 26681767
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Mol Med. 2014 Jul;34(1):205-12
pubmed: 24788627
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Nat Rev Genet. 2014 Sep;15(9):599-612
pubmed: 25022902
Small GTPases. 2011 Jul;2(4):202-210
pubmed: 22145092
Int J Gynecol Cancer. 2010 Apr;20(3):316-22
pubmed: 20375790
Eur Urol. 2013 Jun;63(6):1091-100
pubmed: 23200812
Cancer Res. 2006 Jun 1;66(11):5592-8
pubmed: 16740694
Nat Rev Mol Cell Biol. 2011 Jul 22;12(8):493-504
pubmed: 21779026
Cell Death Differ. 2015 Jan;22(1):22-33
pubmed: 25190144
Cell. 2000 Oct 13;103(2):227-38
pubmed: 11057896
Autophagy. 2016 Aug 2;12(8):1229-39
pubmed: 27171279
J Neurosci. 2014 Jul 16;34(29):9476-83
pubmed: 25031391
Oncol Rep. 2010 Aug;24(2):465-71
pubmed: 20596634
Oncogene. 2016 Aug 4;35(31):4080-90
pubmed: 26686085
J Steroid Biochem Mol Biol. 1997 Aug;62(5-6):391-9
pubmed: 9449242
J Clin Invest. 2012 Apr;122(4):1503-18
pubmed: 22406535
Nat Rev Urol. 2018 Apr;15(4):202
pubmed: 29434365
J Biol Chem. 2013 Jul 12;288(28):20238-47
pubmed: 23720779
Cancer Res. 2009 Apr 1;69(7):2838-44
pubmed: 19276387
Onco Targets Ther. 2011;4:97-113
pubmed: 21792316
PLoS One. 2013 May 17;8(5):e64139
pubmed: 23691160
Cancer Res. 2002 Nov 15;62(22):6418-23
pubmed: 12438227
Mol Cancer Ther. 2016 Mar;15(3):512-22
pubmed: 26832795
Int J Cancer. 2018 May 15;142(10):2040-2055
pubmed: 29250796
Environ Health Perspect. 2001 Aug;109(8):801-8
pubmed: 11564615
Cell Cycle. 2022 May 15;:1-14
pubmed: 35532178
Cancer Res Treat. 2010 Sep;42(3):151-6
pubmed: 20948920
Cancer Res. 2007 Feb 15;67(4):1424-9
pubmed: 17308079
Cell Death Differ. 2020 Feb;27(2):632-645
pubmed: 31243344
Cancer Biomark. 2020;28(1):101-110
pubmed: 32176626
Biochem J. 1992 Jun 1;284 ( Pt 2):539-44
pubmed: 1318034
In Vivo. 2008 Jul-Aug;22(4):493-501
pubmed: 18712178
Clin Exp Metastasis. 2000;18(6):519-25
pubmed: 11592309